SCHEMBL4680307

SCHEMBL4680307

CCOC(=O)c1nc(-c2ccc(C)cc2)c(-c2ccc(Cl)cc2)nc1C(=O)O

nearest known ligand 0.54

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
TARBP2 Q15633 2/20 0.54
MAPT P10636 5/20 0.50
GAA P10253 1/20 0.50
NPSR1 Q6W5P4 1/20 0.50
GPR55 Q9Y2T6 1/20 0.50
GABRA2 P47869 5/20 0.49
GABRB2 P47870 5/20 0.49
CYP19A1 P11511 2/20 0.47
TRPM8 Q7Z2W7 1/20 0.47
DHODH Q02127 1/20 0.46
HTT P42858 1/20 0.46
CYP1A2 P05177 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
ALPL P05186 1/20 0.45
ALOX12 P18054 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4679991 1.00 TARBP2 (0.54) TARBP2MAPTGAANPSR1GPR55
SCHEMBL4680961 0.96 TARBP2 (0.58) TARBP2MAPTNPSR1GABRA2GABRB2
SCHEMBL14101238 0.93 TARBP2 (0.56) TARBP2MAPTGAAGABRA2GABRB2
SCHEMBL27634864 0.88 TARBP2 (0.50) TARBP2MAPTNPSR1GABRA2GABRB2
SCHEMBL27656015 0.88 TARBP2 (0.50) TARBP2MAPTNPSR1GABRA2GABRB2
SCHEMBL4677623 0.87 DHODH (0.52) MAPTGAADHODHCYP1A2CYP2C9
SCHEMBL5752570 0.87 TARBP2 (0.52) TARBP2MAPTNPSR1GABRA2GABRB2
SCHEMBL4677506 0.85 TARBP2 (0.52) TARBP2MAPTGAANPSR1GPR55
SCHEMBL4680694 0.85 TARBP2 (0.52) TARBP2MAPTGAANPSR1GPR55
SCHEMBL4676483 0.83 CNR1 (0.46) MAPTGAADHODHCYP1A2CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1638953-B1 3-SUBSTITUTED 5,6-DIARYL-PYRAZINE-2-CARBOXAMIDE AND -2-SULFONAMIDE DERIVATIVES AS CB1 MODULATORS ASTRAZENECA AB (SE) 2008-08-27 EP disclosed
US-20070093484-A1 3-Substituted 5,6-diaryl-pyrazine-2-carboxamide and -2-sulfonamide derivatives as cb1 modulators ASTRAZENECA AB (SE) 2007-04-26 US disclosed
EP-1638953-A1 3-SUBSTITUTED 5,6-DIARYL-PYRAZINE-2-CARBOXAMIDE AND -2-SULFONAMIDE DERIVATIVES AS CB1 MODULATORS AstraZeneca AB (SE) 2006-03-29 EP disclosed
WO-2004111034-A1 3-SUBSTITUTED 5,6-DIARYL-PYRAZINE-2-CARBOXAMIDE AND -2-SULFONAMIDE DERIVATIVES AS CB1 MODULATORS ASTRAZENECA AB (SE) 2004-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070093484-A1 3-Substituted 5,6-diaryl-pyrazine-2-carboxamide and -2-sulfonamide derivatives as cb1 modulators CNR2, CNR1, FAAH TARBP2 3058/4885MAPT 1463/4885GAA 3433/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.